TRN-110 is under clinical development by Tris Pharma and currently in Pre-Registration for Attention Deficit Hyperactivity Disorder (ADHD). According to GlobalData, Pre-Registration drugs for Attention Deficit Hyperactivity Disorder (ADHD) have an 88% phase transition success rate (PTSR) indication benchmark for progressing into Marketed. GlobalData’s report assesses how TRN-110’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TRN-110 overview
TRN-110 is under development for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatrics and adults. The therapeutic candidate is administered through oral route. It is developed based on liquiXR technology.
Tris Pharma overview
Tris Pharma discovers, develops and commercializes over-the-counter and generic products. The company’s pipeline product candidates include TRN-110, TRN-124, TRN-125, TRN-167, TRN-123, TRN-152, TRN-148, TRN-213, TRN-219, and TRN-226. Its generic products include colesevelam, dexmethylphenidate, dextroamphetamine, doxycycline Hyclate, doxycycline hyclate, droxidopa, febuxostat, hydrocodone, hydrocodone polistirex, lacosamide, methylphenidate, morphine sulfate and paliperidone ER. Tris Pharma is headquartered in South Brunswick, New Jersey, the US.
For a complete picture of TRN-110’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
